Total Clarity Wealth Management Inc. Raises Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Total Clarity Wealth Management Inc. increased its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 8.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 11,333 shares of the biotechnology company’s stock after purchasing an additional 893 shares during the period. Total Clarity Wealth Management Inc.’s holdings in Aurinia Pharmaceuticals were worth $147,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Valeo Financial Advisors LLC purchased a new position in shares of Aurinia Pharmaceuticals in the first quarter worth $29,000. Private Capital Group LLC purchased a new position in shares of Aurinia Pharmaceuticals in the first quarter worth $34,000. Penserra Capital Management LLC increased its stake in shares of Aurinia Pharmaceuticals by 172.2% in the fourth quarter. Penserra Capital Management LLC now owns 2,940 shares of the biotechnology company’s stock worth $40,000 after buying an additional 1,860 shares during the period. Pacifica Partners Inc. increased its stake in shares of Aurinia Pharmaceuticals by 37.7% in the first quarter. Pacifica Partners Inc. now owns 3,650 shares of the biotechnology company’s stock worth $47,000 after buying an additional 1,000 shares during the period. Finally, Lindbrook Capital LLC purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $55,000. 51.21% of the stock is currently owned by institutional investors.

Several research analysts recently commented on AUPH shares. Cantor Fitzgerald lifted their target price on shares of Aurinia Pharmaceuticals from $27.00 to $34.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 26th. SVB Leerink reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Sunday, April 11th. HC Wainwright lifted their price target on shares of Aurinia Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Monday, January 25th. Oppenheimer reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Friday, May 7th. Finally, Royal Bank of Canada cut their price target on shares of Aurinia Pharmaceuticals from $26.00 to $23.00 and set an “outperform” rating on the stock in a report on Friday, May 7th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $26.29.

In other news, Director Jill Leversage purchased 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 11th. The shares were bought at an average price of $10.96 per share, for a total transaction of $27,400.00. Following the purchase, the director now directly owns 3,700 shares in the company, valued at approximately $40,552. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Matthew Maxwell Donley purchased 9,900 shares of the company’s stock in a transaction that occurred on Tuesday, May 11th. The stock was purchased at an average price of $10.07 per share, for a total transaction of $99,693.00. Following the purchase, the vice president now owns 9,900 shares in the company, valued at $99,693. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 18,525 shares of company stock worth $191,722.

Shares of AUPH stock opened at $11.92 on Monday. Aurinia Pharmaceuticals Inc. has a 12 month low of $9.72 and a 12 month high of $20.50. The stock has a market cap of $1.53 billion, a PE ratio of -8.11 and a beta of 0.87. The company’s fifty day moving average price is $12.35 and its 200-day moving average price is $13.93.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Wednesday, May 5th. The biotechnology company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.05). Aurinia Pharmaceuticals had a negative net margin of 173,992.23% and a negative return on equity of 36.98%. Equities research analysts expect that Aurinia Pharmaceuticals Inc. will post -0.91 earnings per share for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Read More: What Is an EV Stock?

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP).

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.